This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Long-term disease-free survival after MIBG therapy for metastatic pheochromocytoma
- Modern Nuclear Imaging for Paragangliomas: Beyond SPECT
- The SNM Practice Guideline for Somatostatin Receptor Scintigraphy 2.0
- Novel SDHD Gene Mutation (H102R) in a Patient With Metastatic Cervical Paraganglioma Effectively Treated by Peptide Receptor Radionuclide Therapy
- Expression of somatostatin receptors, dopamine D2 receptors, noradrenaline transporters, and vesicular monoamine transporters in 52 pheochromocytomas and paragangliomas
- An unusual cause of myocardial infarction
- Comparison of 6-18F-Fluorodopamine PET with 123I-Metaiodobenzylguanidine and 111In-Pentetreotide Scintigraphy in Localization of Nonmetastatic and Metastatic Pheochromocytoma
- Effects of somatostatin analog SOM230 on cell proliferation, apoptosis, and catecholamine levels in cultured pheochromocytoma cells
- Pheochromocytoma: an update on genetics and management
- The diagnosis and management of malignant phaeochromocytoma and paraganglioma
- The optimal imaging of adrenal tumours: a comparison of different methods
- Adrenal incidentalomas -- a continuing management dilemma
- Malignant pheochromocytoma: current status and initiatives for future progress